The Pioneering Role of the Vaccine Safety Datalink Project (VSD) to Advance Collaborative Research and Distributed Data Networks

Introduction: Large-scale distributed data networks consisting of diverse stakeholders including providers, patients, and payers are changing health research in terms of methods, speed and efficiency. The Vaccine Safety Datalink (VSD) set the stage for expanded involvement of health plans in collaborative research. Expanding Surveillance Capacity and Progress Toward a Learning Health System: From an initial collaboration of four integrated health systems with fewer than 10 million covered lives to 16 diverse health plans with nearly 100 million lives now in the FDA Sentinel, the expanded engagement of health plan researchers has been essential to increase the value and impact of these efforts. The collaborative structure of the VSD established a pathway toward research efforts that successfully engage all stakeholders in a cohesive rather than competitive manner. The scientific expertise and methodology developed through the VSD such as rapid cycle analysis (RCA) to conduct near real-time safety surveillance allowed for the development of the expanded surveillance systems that now exist. Building on Success and Lessons Learned: These networks have learned from and built on the knowledge base and infrastructure created by the VSD investigators. This shared technical knowledge and experience expedited the development of systems like the FDA’s Mini-Sentinel and the Patient Centered Outcomes Research Institute (PCORI)’s PCORnet Conclusion: This narrative reviews the evolution of the VSD, its contribution to other collaborative research networks, longer-term sustainability of this type of distributed research, and how knowledge gained from the earlier efforts can contribute to a continually learning health system.

[1]  Steven J. Jacobsen,et al.  The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety , 2011, Pediatrics.

[2]  Barbara Goodson,et al.  Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism , 2010, Pediatrics.

[3]  W Katherine Yih,et al.  Success of program linking data sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. , 2012, Health affairs.

[4]  John F. Steiner,et al.  Sustaining Research Networks: the Twenty-Year Experience of the HMO Research Network , 2014, EGEMS.

[5]  R. Davis Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities , 2013, Pharmaceutics.

[6]  Robert T. Chen,et al.  Active Surveillance of Vaccine Safety: A System to Detect Early Signs of Adverse Events , 2005, Epidemiology.

[7]  M. Manos,et al.  Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? , 2005, Journal of the National Cancer Institute.

[8]  Richard Platt,et al.  The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction , 2012, Pharmacoepidemiology and drug safety.

[9]  John W. Glasser,et al.  Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[10]  R. Platt,et al.  Targeted versus universal decolonization to prevent ICU infection. , 2013, The New England journal of medicine.

[11]  R. Davis,et al.  Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. , 2007, The New England journal of medicine.

[12]  L. Etheredge,et al.  Rapid learning: a breakthrough agenda. , 2014, Health affairs.

[13]  W Katherine Yih,et al.  Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. , 2012, American journal of epidemiology.

[14]  W Katherine Yih,et al.  Intussusception risk after rotavirus vaccination in U.S. infants. , 2014, The New England journal of medicine.

[15]  R. Platt,et al.  Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination , 2012, Pharmacoepidemiology and drug safety.

[16]  Nicola P Klein,et al.  Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. , 2012, JAMA.

[17]  E. Belongia,et al.  Risk of intussusception after monovalent rotavirus vaccination. , 2014, The New England journal of medicine.

[18]  Fang Zhang,et al.  A distributed research network model for post‐marketing safety studies: the Meningococcal Vaccine Study , 2008, Pharmacoepidemiology and drug safety.

[19]  Erin Holve,et al.  Ensuring Support for Research and Quality Improvement (QI) Networks: Four Pillars of Sustainability—An Emerging Framework , 2013, EGEMS.

[20]  W Katherine Yih,et al.  Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project , 2011, Pediatrics.

[21]  R. Platt,et al.  Distributed Health Data Networks: A Practical and Preferred Approach to Multi-Institutional Evaluations of Comparative Effectiveness, Safety, and Quality of Care , 2010, Medical care.

[22]  R. Platt,et al.  Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.

[23]  T. Cheetham,et al.  Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. , 2013, Vaccine.

[24]  Richard Platt,et al.  Four health data networks illustrate the potential for a shared national multipurpose big-data network. , 2014, Health affairs.